A partial agonist of PPARγ prevents paclitaxel‐induced peripheral neuropathy in mice, by inhibiting neuroinflammation
British Journal of Pharmacology2023Vol. 181(7), pp. 1128–1149
Citations Over TimeTop 15% of 2023 papers
Larissa Benvenutti, Fellippe Ramos Wolff, Thiago Patrício Corrêa, Jéssica Melato, Fernanda Capitânio Goldoni, Renata De Faveri, Yasmin Beatrisse Klein Patel, Jade André de Souza, Heloise Adeli Grockoski, Paulo Mateus Nilz, Cléber Luis Bombardelli, Aline Pertile Remor, Karina Giacomini Varela, Natáli Tereza Capistrano Costa, Marcelo Zaldini Hernandes, Mariella Guimarães Lacerda, Kathlen Deruci Rodrigues, Flora Aparecida Milton, Francisco de Assis Rocha Neves, Maria Eduarda Signorini Pereira, Elaine Cristina Kormann Imianowsky, Fátima de Campos Buzzi, Victor Hugo Brunaldi Marutani, Luis Carlos Stoeberl, Rogério Corrêa, Sarah Eller, Tiago Franco de Oliveira, Thamires Bragança Paduam Gonçalves, Raquel Costa da Silva, Giselle F. Passos, Robson da Costa, José Roberto Santin, Nara Lins Meira Quintão
Abstract
TZD-A1, a partial agonist of PPARγ, provided neuroprotection and reduced hypersensitivity induced by paclitaxel. Allied to its safety profile and good bioavailability, TZD-A1 is a promising drug candidate to prevent and treat CIPN in cancer patients.
Related Papers
- → Serum Levels of Mature Brain-Derived Neurotrophic Factor (BDNF) and Its Precursor proBDNF in Healthy Subjects(2012)53 cited
- → Effect of fat free mass on serum and plasma BDNF concentrations during exercise and recovery in healthy young men(2013)34 cited
- → Elucidating the Role of Brain-Derived Neurotrophic Factor in the Brain(2007)20 cited
- → Evaluation of brain-derived neurotrophic factor in diabetic rats(2014)14 cited
- → The brain-derived neurotrophic factor (BDNF) system as a therapeutical target for development of drugs restoring innervation(2017)